Multiple sclerosis associated fatigue during natalizumab treatment

Multiple Sclerosis-Associated Fatigue during Disease-Modifying Treatment with Natalizumab, Interferon-Beta and Glatiramer Acetate

“…Given the marked reduction of clinical and MRI parameters for inflammatory activity in comparison to IFN and GA, this effect could be attributable to a more pronounced decrease of inflammatory CNS activity with NTZ. Our results in longer-term NTZ-treated patients complement results from a previous short-term prospective study [10] . Findings for the control group were similar to previous analyses from the same database [3] .…”

“…Findings for the control group were similar to previous analyses from the same database [3] . Fatigue was independent from most important patient characteristics, which underlines that we examined a common construct of fatigue [3,[8][9][10] . A reduction of fatigue during NTZ treatment represents a relevant, additional treatment benefit for improved quality of life.…”

Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab

“…13,14,24,25 ENER-G is the largest prospective study to evaluate fatigue and cognition during natalizumab treatment, and to examine correlations between the two. Both fatigue and cognitive decline can be debilitating for MS patients.…”

Multiple Sclerosis Symptom Recrudescence at the End of the Natalizumab Dosing Cycle

“…1 Furthermore, some natalizumab-treated patients experience subjective improvement in functional status, mood, fatigue level, and cognitive function. [2][3][4][5][6] Natalizumab is administered as a 300-mg intravenous infusion every 4 weeks. The mean half-life of natalizumab in MS patients is 11 days (SD 4 days).…”